ATLATL Beijing Darts International Innovation Platform Fully Operational, Accelerating the Formation of a World-Class Innovation Cluster

On August 26, 2023, Phase II of the ATLATL Beijing International Innovation Platform, located in the Zhongguancun Life Science Park, officially commenced operations, marking the full launch of the ATLATL Beijing International Innovation Platform. Attending the inauguration ceremony were Liu Qiang, Deputy Director of the Future Science City Administrative Committee (Life Science Park Administrative Committee) and Member of the Party Leadership Group and Deputy District Mayor (concurrently) of the Changping District People’s Government; Yang Pengyu, Director of the Innovation and Entrepreneurship Division of the Beijing Municipal Science & Technology Commission and the Zhongguancun Administrative Committee; Jin Yi, Director of the Pharmaceutical and Health Industry Division of the Future Science City Administrative Committee (Life Science Park Administrative Committee); Wang Ying, Chairman of Beijing Changping Science Park Development Co., Ltd.; and Chen Junhao, Deputy General Manager of Beijing Zhongguancun Technology Service Co., Ltd., among other relevant leaders.

Inauguration Ceremony for the Full Launch of the Beijing Feibiao International Innovation Platform

As a strong support for Changping District’s efforts to create a “nuclear explosion point” for Beijing’s pharmaceutical and health industry, Zhongguancun Life Science Park has adhered to the “dual improvement” of both soft and hard environments, introducing the Beijing Feibiao International Innovation Platform (hereinafter referred to as “Beijing Feibiao”) in 2021. As of the end of July 2023, Beijing Feibiao had helped more than 20 biomedical innovation teams accelerate their development, with total corporate financing exceeding RMB 2 billion.

At the event, Liu Qiang, Deputy Director of the Future Science City Administrative Committee (Life Science Park Administrative Committee) and Member of the Party Leadership Group and Deputy District Mayor (concurrently serving) of the Changping District People’s Government, delivered an address.

 Liu Qiang, Deputy Director of the Science City Administrative Committee (Life Park Administrative Committee), Member of the Party Leadership Group of the Changping District People's Government, and Deputy District Mayor (concurrently)

Liu Qiang stated that striving to become a globally influential center for scientific and technological innovation is an inevitable choice for Beijing to achieve high-quality development. Changping District has proactively integrated into the overall framework of building Beijing into an international center for scientific and technological innovation and advancing the construction of the “Two Zones.” The introduction of the Feibiao International Innovation Platform represents a significant measure by Changping District to accelerate the development of the “Life Valley” into a world-leading hub. As a first-class research acceleration platform, Feibiao possesses profound insights into the industrial ecosystem and demonstrates innovative practices. What makes it particularly valuable is that Feibiao not only supports the innovative R&D efforts of various enterprises but also establishes multi-dimensional, in-depth collaborations with resident companies, thereby creating a unique ecosystem. Looking ahead, we hope Feibiao will continue to leverage its leading advantages by linking international resources and building bridges for global innovation. It aims to comprehensively promote and deepen the application of the world’s most cutting-edge technologies and platforms in Beijing, striving to establish a “Beijing Model” for the innovative development of China’s biopharmaceutical industry.

Dr. Zhu Pengcheng, Founder and CEO of ATLATL

Dr. Zhu Pengcheng, Founder and CEO of ATLATL, stated that over the two years since establishing its presence in Beijing, ATLATL has leveraged its strengths in hard-core R&D to build the Beijing Feibiao International Innovation Platform, focusing on innovation aggregation and origination. “Beijing has ranked among the top three global science and technology clusters, boasting a solid scientific foundation, a concentration of high-caliber scientists, and highly active innovation entities. We are deeply grateful for the care and support from government leaders at all levels and various commissions and bureaus, the strong assistance from our partners, and the trust placed in us by our innovation teams and clients. The Beijing Feibiao International Innovation Platform is now fully operational. Moving forward, we will continue to cultivate a rich and diverse innovation system and ecosystem, continuously improving the innovation chain from basic research and applied research to industrial application. We are committed to providing tangible services to innovation teams in areas such as talent aggregation, investment and financing, acceleration of industrial translation, headquarters functions, and collaborative development, helping enterprises reach their next milestones more rapidly.”

ATLATL is committed to gaining insights into the pulse of scientific innovation and development from a global perspective, thereby expanding the boundaries of the innovation ecosystem. As a vital component in building this ecosystem, ATLATL continuously establishes connections with leading global R&D forces and engages in deep collaborations with multinational pharmaceutical companies such as Novo Nordisk and Boehringer Ingelheim, empowering local Chinese innovation and the advancement of global life sciences. At the event, Ms. Han Dan, Corporate Vice President of Novo Nordisk and President of its China R&D Center, and Ms. Yu Bingke, Head of the External Innovation Center at Boehringer Ingelheim, attended and delivered speeches.

Beijing Feibiao has partnered with Boehringer Ingelheim to jointly establish the BI-ATLATL Joint Laboratory, providing comprehensive support for innovative biopharmaceutical projects, including proof of concept, patent strategy, R&D services, and commercial collaboration. Additionally, it has co-established the MITC Innovation Technology Center with Miltenyi Biotec to build a new ecosystem of open innovation and collaboration in the field of cell and gene therapy (CGT), working together with innovative project companies to create diversified R&D pipelines.

Leveraging its robust core capabilities, ATLATL has not only attracted multinational corporations but also numerous renowned research institutions to jointly establish collaborative platforms. At the launch ceremony, Beijing Feibiao International Innovation Platform signed cooperation agreements for joint platform development with leading upstream and downstream industry players such as Waters Corporation and Danaher, working together to empower new drug R&D. Mr. Xu Bing, President of Waters China, and Mr. Zhu Lin, Director of Strategic Marketing for Life Sciences at Danaher, attended the ceremony.

The Beijing Feibiao International Innovation Platform has a total construction area of 8,600 square meters and features Class A R&D spaces, including more than 30 laboratories, two sets of Grade B+C universal GMP facilities, and one PCR clinical testing center. It provides tenant companies with R&D spaces and professional facilities equivalent to those offered by multinational pharmaceutical enterprises.

At the event, the first batch of clients for Phase II of the Beijing International Innovation Platform for Biotech formally signed agreements to move in: Shenyuanzhiyao Biotechnology (Beijing) Co., Ltd., Ruiyu (Beijing) Biopharmaceutical Co., Ltd., Beijing Molecule Mind Technology Co., Ltd., Beijing Weiyuan Digital Intelligence Biotechnology Co., Ltd., Beijing Hemu Biotechnology Co., Ltd., and Beisai Hongsheng (Beijing) Biotechnology Co., Ltd.

At the subsequent thematic salon on the translation of biomedical research achievements, experts and scholars from the scientific research community as well as industry representatives shared insights on topics such as “Challenges and Prospects of Cell Therapy,” “How Multi-Omics Technologies Empower Pharmaceutical R&D,” “Unveiling the Mysteries of Life with High-Throughput, Automated Mass Spectrometry,” and “Interactive R&D Facilitating Proof-of-Concept.”

The launch ceremony also marked the second anniversary of the establishment of the Beijing Feibiao International Innovation Platform. Over the past two years, more than ten innovative teams, including Shenji Changhua, Huashen Zhiyao, Shenyuanzhi Yao, and Yinuoweikang, have joined Beijing Feibiao. Their projects cover R&D and innovation in areas such as drug development, gene editing, novel therapeutic technologies, and AI-driven drug design. Notably, the Shenji Changhua team, which focuses on neurological diseases such as amyotrophic lateral sclerosis (ALS), achieved a “move-in-ready” setup at Feibiao. This eliminated the need for months-long laboratory construction and equipment procurement, allowing the team to devote itself fully to scientific research and technology transfer from day one. With the support of the Beijing Feibiao International Innovation Platform, Shenji Changhua has experienced rapid growth over the past year, and its therapeutic solution has successfully entered clinical trials.

To support more innovation and entrepreneurship teams, Beijing ATLATL will further expand its platform scale and continuously enhance its service capabilities. According to Jiang Maohua, head of the Beijing ATLATL International Innovation Platform, ATLATL plans to build the “Life Valley ATLATL Innovation Complex” in the Life Science Park, with a total construction area of approximately 75,000 square meters. The project includes over 50,000 square meters dedicated to industrialization and R&D translation platforms, aiming to accelerate the development of the biopharmaceutical industry in Changping’s “Life Valley.”

On the fertile ground of innovation that is Beijing, Feibiao has cultivated an open, international, and highly dynamic ecosystem for innovative collaboration. High-potential innovative startups optimize their development pathways, reduce innovation costs, and shorten trial-and-error cycles through Feibiao’s support, while leveraging global top-tier resources to accelerate their growth. Meanwhile, renowned enterprises and institutions collaborating with ATLATL can identify promising innovative technologies at the earliest stage and rapidly facilitate the commercialization of these innovations through diverse empowerment strategies.

By aggregating and originating innovation, ATLATL rapidly connects the “seeds” of Beijing’s biopharmaceutical innovation with international innovation resources, building a globally leading biopharmaceutical innovation platform and a world-class innovation cluster to accelerate the development of Changping, Beijing into the “Life Valley” with global leadership!

Beijing Feibiao International Innovation Platform is an integrated innovation hub in the life and health technology sector, combining R&D centers, accelerated commercialization, and early-stage incubation. Designed and constructed to meet the standards of top-tier international biopharmaceutical R&D laboratories, it features Class A R&D laboratory spaces, complemented by high-quality office and business facilities. The platform gathers diverse global innovation elements, including multinational corporations, leading domestic pharmaceutical companies, universities, research institutes, and medical institutions. By integrating cutting-edge R&D resources, it provides tenant enterprises with advanced R&D equipment, meticulous laboratory operations and EHS (Environment, Health, and Safety) management, professional on-site CRO technical support, a comprehensive R&D assembly management system, and well-developed supporting resources, thereby facilitating the rapid translation of frontier technologies into practical applications.